Educational Purposes The longterm outcome of pulmonary embolism
Educational Purposes
The long-term outcome of pulmonary embolism
Recurrent VTE in patients with DVT or PE
Main studies on risk of recurrent VTE and optimal duration of OAC therapy in patients with
Risk factors for recurrent VTE after 3 months of anticoagulation
Lessons from 10 years of prospective cohort studies and randomized clinical trials
The risk of fatal pulmonary embolism after stopping anticoagulant therapy in patients wit
Inception cohort at baseline
Classification of fatal PE
Results: incidence of fatal PE
The risk of recurrent vte after discontinuing anticoagulation in patients with DVT
Recurrent VTE after stopping anticoagulation in 1626 patients with VTE
Patient outcomes after Deep Vein Thrombosis and Pulmonary Embolism
Life table estimates of cumulative incidence rate of selected outcomes
WODIT PE: cumulative recurrent VTE
Risk of recurrent PE in patients with symptomatic PE
Clinical predictors for fatal pulmonary embolism in 15, 520 patients with venous thromboemb
Predictive factors for fatal PE
Chronic thromboembolic pulmonary hypertension
Epidemiology of CTEPH: old studies
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism
Cumulative incidence of CTEPH after a first episode of PE without prior DVT
Risk factors for CTEPH
Main implication
Other potential predictors of CTPH
New perspectives for improving the long-term outcome of patients with PE
Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary e
Cumulative probability of event-free survival
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboe
PREVENT Results
Comparison of low-intensity warfarin therapy with conventionalintensity warfarin therapy
ELATE Study
D-dimer testing to determine the duration of anticoagulant therapy
The Prolong study
D-Dimer test to determine the duration of OAT
Pulmonary embolism: Prolong extension study
Idraparinux in the secondary prevention of VTE
Van Gogh Extension: recurrent VTE
Van Gogh Extension: major bleeding
Oral antithrombotic drugs in research
Development of subsequent cardiovascular events
Venous thromboembolism and subsequent hospitalization due to acute cardiovascular events
Results: first year of follow-up
Results: 2– 20 years of follow-up
Risk of acute myocardial infarction and stroke
Risk of acute myocardial infarction and stroke in relation to the length of the follow-up
Comments (1)
Comments (2)
- Slides: 48